VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China

European Journal of Clinical Pharmacology

Volumn 66, Issue 12, 2010, Pages 1217-1227

  Gu, Qiang ^a   Kong, Yan ^a   Schneede, Jörn ^b   Xiao, Ying Bin ^a   Chen, Lin ^a   Zhong, Qian Jin ^a   Wang, Xue Feng ^a   Hao, Jia ^a   Chen, Bai Cheng ^a   Chen, Jing Jin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C9; EPHX1691A>G; Gene polymorphism; Mechanical heart valve prostheses; SNP; Southwest Han Chinese patients; VKORC1 1639G>A; Warfarin therapy

Indexed keywords

ADENINE; CYTOCHROME P450 2C9; CYTOSINE; EPOXIDE HYDROLASE; GUANINE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CHINA; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; SEQUENCE ANALYSIS;

ADULT; AGE FACTORS; AGED; BODY WEIGHT; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HEART VALVE PROSTHESIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; WARFARIN;

EID: 78649322561     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0863-9     Document Type: Article

References (46)

1. AK Daly BP King 2003 Pharmacogenetics of oral anticoagulants Pharmacogenetics 13 5 247 252 1:CAS:528:DC%2BD3sXksVWks78%3D 10.1097/00008571-200305000-00002 12724615 (Pubitemid 36583990)
2. CS Landefeld RJ Beyth 1993 Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention Am J Med 95 3 315 328 1:STN:280:DyaK3sznslKruw%3D%3D 10.1016/0002-9343(93)90285-W 8368229 (Pubitemid 23270290)
3. L Miao J Yang C Huang Z Shen 2007 Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients Eur J Clin Pharmacol 63 12 1135 1141 1:CAS:528:DC%2BD2sXht1yit7zM 10.1007/s00228-007-0381-6 17899045 (Pubitemid 350112769)
4. E Shikata I Ieiri S Ishiguro H Aono 2004 Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity Blood 103 7 2630 2635 1:CAS:528:DC%2BD2cXjtVaks7o%3D 10.1182/blood-2003-09-3043 14656880 (Pubitemid 38393017)
5. GP Aithal CP Day PJ Kesteven AK Daly 1999 Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 9154 717 719 1:STN:280:DyaK1M7ntFGhsQ%3D%3D 10.1016/S0140-6736(98)04474-2 10073515 (Pubitemid 29103806)
6. M Wadelius LY Chen K Downes J Ghori S Hunt N Eriksson, et al. 2005 Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 4 262 270 1:CAS:528:DC%2BD2MXmsVyjs78%3D 10.1038/sj.tpj.6500313 15883587 (Pubitemid 41131718)
7. M Wadelius LY Chen N Eriksson S Bumpstead J Ghori C Wadelius, et al. 2007 Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 1 23 34 1:CAS:528:DC%2BD2sXhsFCgs78%3D 10.1007/s00439-006-0260-8 17048007 (Pubitemid 46421137)
8. M Wadelius LY Chen JD Lindh N Eriksson MJ Ghori S Bumpstead, et al. 2009 The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 4 784 792 1:CAS:528:DC%2BD1MXhtlGhsbc%3D 10.1182/blood-2008-04-149070 18574025
9. HD Chern TH Ueng YP Fu CW Cheng 2006 CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese Clin Chim Acta 367 1-2 108 113 1:CAS:528:DC%2BD28Xjs1Wrtbg%3D 10.1016/j.cca.2005.11.026 16413010
10. R Loebstein M Vecsler D Kurnik N Austerweil E Gak H Halkin, et al. 2005 Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9 Clin Pharmacol Ther 77 5 365 372 1:CAS:528:DC%2BD2MXktFCrt7Y%3D 10.1016/j.clpt.2005.01.010 15900282 (Pubitemid 40719265)
11. C Hassett L Aicher JS Sidhu CJ Omiecinski 1994 Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants Hum Mol Genet 3 3 421 428 1:CAS:528:DyaK2cXksFaqtbw%3D 10.1093/hmg/3.3.421 7516776
12. CJ Omiecinski C Hassett V Hosagrahara 2000 Epoxide hydrolase-polymorphism and role in toxicology Toxicol Lett 112-113 365 370 10.1016/S0378-4274(99) 00235-0 10720753 (Pubitemid 30138145)
13. C Hassett J Lin CL Carty EM Laurenzana CJ Omiencinski 1997 Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression Arch Biochem Biophys 337 2 275 283 1:CAS:528:DyaK2sXlsVOmtQ%3D%3D 10.1006/abbi.1996.9794 9016823 (Pubitemid 27198192)
14. TL Wang HL Li WY Tjong QS Chen GS Wu, et al. 2008 Genetic factors contribute to patient-specific warfarin dose for Han Chinese Clin Chim Acta 396 1-2 76 79 1:CAS:528:DC%2BD1cXhtVKmsr3K 10.1016/j.cca.2008.07.005 18680736
15. A Gsur T Zidek K Schnattinger E Feik G Haidinger P Hollaus 2003 Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk Br J Cancer 89 4 702 706 1:CAS:528:DC%2BD3sXmtFKqsbo%3D 10.1038/sj.bjc.6601142 12915882 (Pubitemid 37076177)
16. M Wenghoefer B Pesch V Harth P Broede S Fronhoffs O Landt 2003 Association between head and neck cancer and microsomal epoxide hydrolase genotypes Arch Toxicol 77 1 37 41 1:CAS:528:DC%2BD38Xps1Wgur0%3D 10.1007/s00204-002-0414-y 12491039 (Pubitemid 36056981)
17. R Loebstein I Dvoskin H Halkin M Vecsler A Lubetsky G Rechavi, et al. 2007 A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance Blood 109 6 2477 2480 1:CAS:528:DC%2BD2sXnslygsLk%3D 10.1182/blood-2006-08- 038984 17110455 (Pubitemid 46425891)
18. C Geisen M Watzka K Sittinger 2005 VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb Haemost 94 4 773 779 16270629
19. SW Huang HS Chen XQ Wang 2009 Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients Pharmacogenet Genomics 19 3 226 234 1:CAS:528:DC%2BD1MXjsVWqsbk%3D 10.1097/FPC.0b013e328326e0c7 19177029
20. HS Kim SS Lee M Oh YJ Jang 2009 Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement Pharmacogenet Genomics 19 2 103 112 1:CAS:528: DC%2BD1MXmvVaktA%3D%3D 10.1097/FPC.0b013e32831a9ae3 19077919
21. MS Wen M Lee JJ Chen 2008 Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes Clin Pharmacol Ther 84 1 83 89 1:CAS:528:DC%2BD1cXnt1KqsL4%3D 10.1038/sj.clpt.6100453 18183038 (Pubitemid 351861488)
22. DL Veenstra JH You MJ Rieder 2005 Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenet Genomics 15 10 687 691 1:CAS:528: DC%2BD2MXpslahtLc%3D 10.1097/01.fpc.0000174789.77614.68 16141794
23. Y Uetsuka S Hosoda H Kasanuki M Aosaki K Murasaki K Ooki, et al. 2000 Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to PT-INR Heart Vessels 15 3 124 128 1:STN:280:DC%2BD3M7pvVCjsg%3D%3D 10.1007/PL00007265 11289500
24. Y Kanaoka K Tanemoto T Murakami K Kuroki 2000 Thromboembolic and bleeding complications in patients treated with oral anticoagulant therapy after mechanical heart valve prostheses implantation Kyobu Geka 53 9 754 758 1:STN:280:DC%2BD3M%2FhsFyjsQ%3D%3D 10935402
25. M Kitamura H Koyanagi S Kawada Y Hosoda H Kurosawa 1999 Optimum anticoagulation control after bileaflet mechanical valve replacement: a prospective multi-institutional study Kyobu Geka 52 12 1001 1004 1:STN:280:DC%2BD3c%2Fit1WgtA%3D%3D 10554485
26. HY Chen QL Ding LW Zhang 2008 The application of thrombin generation tests to warfarin anticoagulation monitoring Zhonghua Xue Ye Xue Za Zhi 29 3 168 170 18788615
27. JG Hu JM Li JF Yu L Jiang 2004 Anticoagulation in Chinese patients with carbomedics mechanical prosthetic heart valves Zhong Nan Da Xue Xue Bao Yi Xue Ban 29 4 460 462 16134606
28. H Takahashi T Kashima S Kimura 1997 Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection J Chromatogr B Biomed Sci Appl 701 1 71 80 1:CAS:528:DyaK2sXntVOntL8%3D 10.1016/S0378-4347(97)00346-0 9389340 (Pubitemid 27473961)
29. R Lombardi V Chantarangkul M Cattaneo A Tripodi 2003 Measurement of warfarin in plasma by high performance liquid chromatography HPLC and its correlation with the international normalized ratio Thromb Res 111 4-5 281 284 1:CAS:528:DC%2BD3sXhtVSjtbfP 10.1016/j.thromres.2003.09.006 14693176 (Pubitemid 38021948)
30. LH Liao H Zhang MP Lai KW Lau AK Lai JH Zhang, et al. 2007 The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese Clin Chim Acta 380 1-2 191 196 1:CAS:528:DC%2BD2sXjslSlurs%3D 10.1016/j.cca.2007.02.033 17368604 (Pubitemid 46522485)
31. DL Veenstra JH You MJ Rieder FM Farin HW Wilkerson DK Blough, et al. 2005 Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenet Genomics 15 10 687 691 1:CAS:528:DC%2BD2MXpslahtLc%3D 10.1097/01.fpc.0000174789.77614.68 16141794
32. M Yoshizawa H Hayashi Y Tashiro S Sakawa H Moriwaki T Akimoto, et al. 2009 Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients Thromb Res 124 2 161 166 1:CAS:528:DC%2BD1MXms1Wht7o%3D 10.1016/j.thromres.2008.11.011 19135231
33. MJ Rieder AP Reiner BF Gage 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 22 2285 2293 1:CAS:528:DC%2BD2MXksl2ltrk%3D 10.1056/NEJMoa044503 15930419 (Pubitemid 40740552)
34. M Kimura I Ieiri K Mamiya A Urae S Higuchi 1998 Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population Ther Drug Monit 20 3 243 247 1:CAS:528:DyaK1cXjvVChs7k%3D 10.1097/00007691-199806000-00001 9631918 (Pubitemid 28248841)
35. L Bodin C Verstuyft DA Tregouet A Robert L Dubert C Funck-Brentano, et al. 2005 Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity Blood 106 1 135 140 1:CAS:528:DC%2BD2MXlvVWjsLo%3D 10.1182/blood-2005-01-0341 15790782 (Pubitemid 40967184)
36. M Wadelius K Sörlin O Wallerman J Karlsson QY Yue PK Magnusson, et al. 2004 Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors Pharmacogenomics 4 1 40 48 1:CAS:528:DC%2BD2cXltFantw%3D%3D 10.1038/sj.tpj.6500220 (Pubitemid 38256604)
37. N Wajih DC Sane SM Hutson R Wallin 2004 The inhibitory effect of calumenin on the vitamin K-dependent γ-carboxylation system. Characterization of the system in normal and warfarin-resistant rats J Biol Chem 279 24 25276 25283 1:CAS:528:DC%2BD2cXksFygsrg%3D 10.1074/jbc.M401645200 15075329 (Pubitemid 38756780)
38. LE Visser PH Trienekens PA De Smet AG Vulto A Hofman, et al. 2005 Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants Pharmacogenet Genomics 15 2 69 74 1:CAS:528:DC%2BD2MXivFGjt7c%3D 10.1097/01213011-200502000-00002 15861030
39. S Rost A Fregin V Ivaskevicius E Conzelmann K Hörtnagel HJ Pelz, et al. 2004 Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature 427 6974 537 541 1:CAS:528: DC%2BD2cXpsFWhtQ%3D%3D 10.1038/nature02214 14765194 (Pubitemid 38209110)
40. HJ Cho KH Sohn HM Park KH Lee B Choi S Kim, et al. 2007 Factors affecting the inter-individual variability of warfarin dose requirement in adult Korean patients Pharmacogenomics 8 4 329 337 1:CAS:528:DC%2BD2sXjs1Srtro%3D 10.2217/14622416.8.4.329 17391071 (Pubitemid 46585496)
41. D Herman I Locatelli I Grabnar P Peternel M Stegnar A Mrhar, et al. 2005 Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose Pharmacogenomics 5 3 193 202 1:CAS:528:DC%2BD2MXktlCmt7Y%3D 10.1038/sj.tpj.6500308 (Pubitemid 40852221)
42. MD Caldwell RL Berg KQ Zhang I Glurich JR Schmelzer SH Yale, et al. 2007 Evaluation of genetic factors for warfarin dose prediction Clin Med Res 5 1 8 16 1:CAS:528:DC%2BD2sXhtFClu7vL 10.3121/cmr.2007.724 17456829 (Pubitemid 350218774)
43. H Takahashi GR Wilkinson EA Nutescu T Morita MD Ritchie MG Scordo, et al. 2006 Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogenet Genomics 16 2 101 110 1:CAS:528:DC%2BD28Xls1Gksg%3D%3D 10.1097/01.fpc.0000184955.08453.a8 16424822
44. EA Sconce TI Khan HA Wynne P Avery L Monkhouse BP King, et al. 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 7 2329 2333 1:CAS:528:DC%2BD2MXhtVKqt7%2FL 10.1182/blood-2005-03-1108 15947090 (Pubitemid 41510803)
45. UI Schwarz MD Ritchie Y Bradford C Li SM Dudek A Frye-Anderson, et al. 2008 Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 100 999 1008 1:CAS:528:DC%2BD1cXjtVSrsLs%3D 10.1056/NEJMoa0708078 18322281 (Pubitemid 351347099)
46. D Herman I Locatelli I Grabnar P Peternel M Stegnar M Lainscak, et al. 2006 The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose Eur J Clin Pharmacol 62 4 291 296 1:CAS:528:DC%2BD28Xjt1CltLo%3D 10.1007/s00228-006-0104-4 16552506